UBS China Healthcare: Expert Call Takeaways — Key Debates on the Application of AI in Internet Healthcare
Summaries are public. PDF access requires an active membership; all members have the same access. Sign in
UBS hosted an expert call examining the application of artificial intelligence in China's internet healthcare sector. The expert noted that medical large language models developed by internet healthcare firms outperform generalist LLMs in clinical scenarios, ranking higher on benchmarks like MedBench due to evidence-based training methodologies utilizing clinical guidelines and patient records. Ant Group currently leads in this space, leveraging Alibaba's vast ecosystem for superior data collection and a multi-agent approach through its AI application, Ant Afu, which focuses on high-frequency health management interactions. However, the expert questioned whether Afu can sustain user engagement over time given historical failures in health-tech adoption. Currently, medical LLMs roughly match the competence of China's associate chief physicians, though reaching the level of top specialists remains several years away due to training data constraints. Monetization avenues for these models may include e-commerce commissions, hardware partnerships, and pharmaceutical patient education. UBS believes that while AI advancements can boost market sentiment and unlock long-term monetization, the direct earnings contribution to companies like AliHealth and JD Health is very limited in the short term. Investors remain concerned about excessive valuations and a lack of immediate earnings catalysts, potentially putting these stocks under near-term pressure.